No Level 4 CDC Travel Health Notice (“Avoid All Travel”) has been issued as of late May 2026, with all active alerts capped at Level 3 or below despite the ongoing Ebola outbreak in the Democratic Republic of the Congo, Uganda, and South Sudan. Official CDC guidance relies on targeted entry screening, 30-day restrictions for certain travelers, and Level 3 reconsideration notices rather than blanket avoidance, reflecting contained transmission and available precautions under current epidemiological data. Recent lower-tier alerts for dengue and polio further illustrate routine management of outbreaks without escalation to extreme-risk thresholds. With roughly seven months remaining, the absence of novel high-severity pathogens or rapid case surges supports trader consensus favoring no issuance by year-end, though evolving surveillance or unexpected viral spread could alter that assessment.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourLe CDC émet un avertissement de niveau 4 d'ici le 31 décembre ?
Le CDC émet un avertissement de niveau 4 d'ici le 31 décembre ?
Oui
$71,809 Vol.
$71,809 Vol.
31 déc. 2026
Oui
$71,809 Vol.
$71,809 Vol.
31 déc. 2026
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.No Level 4 CDC Travel Health Notice (“Avoid All Travel”) has been issued as of late May 2026, with all active alerts capped at Level 3 or below despite the ongoing Ebola outbreak in the Democratic Republic of the Congo, Uganda, and South Sudan. Official CDC guidance relies on targeted entry screening, 30-day restrictions for certain travelers, and Level 3 reconsideration notices rather than blanket avoidance, reflecting contained transmission and available precautions under current epidemiological data. Recent lower-tier alerts for dengue and polio further illustrate routine management of outbreaks without escalation to extreme-risk thresholds. With roughly seven months remaining, the absence of novel high-severity pathogens or rapid case surges supports trader consensus favoring no issuance by year-end, though evolving surveillance or unexpected viral spread could alter that assessment.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Marché ouvert : Jan 19, 2026, 3:15 PM ET
Volume
$71,809Date de fin
31 déc. 2026Marché ouvert
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.No Level 4 CDC Travel Health Notice (“Avoid All Travel”) has been issued as of late May 2026, with all active alerts capped at Level 3 or below despite the ongoing Ebola outbreak in the Democratic Republic of the Congo, Uganda, and South Sudan. Official CDC guidance relies on targeted entry screening, 30-day restrictions for certain travelers, and Level 3 reconsideration notices rather than blanket avoidance, reflecting contained transmission and available precautions under current epidemiological data. Recent lower-tier alerts for dengue and polio further illustrate routine management of outbreaks without escalation to extreme-risk thresholds. With roughly seven months remaining, the absence of novel high-severity pathogens or rapid case surges supports trader consensus favoring no issuance by year-end, though evolving surveillance or unexpected viral spread could alter that assessment.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Volume
$71,809Date de fin
31 déc. 2026Marché ouvert
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...No Level 4 CDC Travel Health Notice (“Avoid All Travel”) has been issued as of late May 2026, with all active alerts capped at Level 3 or below despite the ongoing Ebola outbreak in the Democratic Republic of the Congo, Uganda, and South Sudan. Official CDC guidance relies on targeted entry screening, 30-day restrictions for certain travelers, and Level 3 reconsideration notices rather than blanket avoidance, reflecting contained transmission and available precautions under current epidemiological data. Recent lower-tier alerts for dengue and polio further illustrate routine management of outbreaks without escalation to extreme-risk thresholds. With roughly seven months remaining, the absence of novel high-severity pathogens or rapid case surges supports trader consensus favoring no issuance by year-end, though evolving surveillance or unexpected viral spread could alter that assessment.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes